PiR-hsa-4447944 serves as an oncogenic mediator in prostate cancer and promotes the development of castration resistance by inhibiting NEFH expression
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 12 samples: 3 × LNCaP-piR-Ctrl vs 3 × LNCaP-piR-hsa-4447944 vs 3 × 22RV1-piR-Ctrl vs 3 × 22RV1-piR-hsa-4447944Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- PiRNA-4447944 promotes castration-resistant growth and metastasis of prostate cancer by inhibiting NEFH expression through forming the piRNA-4447944-PIWIL2-NEFH complexInternational journal of biological sciences · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE248169_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1041862 and SRA study SRP472643. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7906763 LNCaP-piR-Ctrl-1 LNCaP-piR-Ctrl
- GSM7906764 LNCaP-piR-Ctrl-2 LNCaP-piR-Ctrl
- GSM7906765 LNCaP-piR-Ctrl-3 LNCaP-piR-Ctrl
- GSM7906766 LNCaP-piR-hsa-4447944-1 LNCaP-piR-hsa-4447944
- GSM7906767 LNCaP-piR-hsa-4447944-2 LNCaP-piR-hsa-4447944
- GSM7906768 LNCaP-piR-hsa-4447944-3 LNCaP-piR-hsa-4447944
- GSM7906769 22RV1-piR-Ctrl-1 22RV1-piR-Ctrl
- GSM7906770 22RV1-piR-Ctrl-2 22RV1-piR-Ctrl
- GSM7906771 22RV1-piR-Ctrl-3 22RV1-piR-Ctrl
- GSM7906772 22RV1-piR-hsa-4447944-1 22RV1-piR-hsa-4447944
- GSM7906773 22RV1-piR-hsa-4447944-2 22RV1-piR-hsa-4447944
- GSM7906774 22RV1-piR-hsa-4447944-3 22RV1-piR-hsa-4447944
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE325471 The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication 12 samples shares castration, prostate
- GSE230601 ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer [RNA-seq] 12 samples shares resistance, prostate
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.